Skip to main content

Colesevelam Disease Interactions

There are 5 disease interactions with colesevelam:

Major

Colesevelam (applies to colesevelam) diabetic ketoacidosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Type 1

Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.

Major

Colesevelam (applies to colesevelam) gastrointestinal disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastroparesis, Dysphagia

The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction. Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction. Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.

Major

Colesevelam (applies to colesevelam) TG

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hyperlipidemia, Pancreatitis

The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL. Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations. Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter. Caution should be exercised when treating patients with TG levels greater than 300 mg/dL. Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.

Moderate

Bile acid sequestrants (applies to colesevelam) PKU

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phenylketonuria

Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose. Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose. WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics). Regular Colestid, Questran and LoCholest do not contain phenylalanine.

References

  1. "Product Information. Questran Light (cholestyramine)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Questran (cholestyramine)." Par Pharmaceutical Inc, Chestnut Ridge, NY.
  3. "Product Information. Colestid (colestipol HCI)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Colesevelam (applies to colesevelam) malabsorption syndromes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vitamin A Deficiency, Vitamin D Deficiency, Vitamin K Deficiency

Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K. Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins. The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.

Colesevelam drug interactions

There are 87 drug interactions with colesevelam

Colesevelam alcohol/food interactions

There are 2 alcohol/food interactions with colesevelam

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.